InnoCare Releases 2024 Results and Business Highlights
InnoCare announced 2024 annual results, including financials, R&D progress in oncology and autoimmune diseases, and globalization efforts.
March 27, 2025
by PharmaSources
A Decade of Transformation in China's Innovative Drug Industry: The Journey from Follower to Leader
Over the past decade, China's innovative drug market has experienced remarkable transformation and growth. With the combined drive of policies, technology, and capital, China's innovative drug industry has entered a golden period of growth. This paper pro
March 14, 2025
by Kevin
Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing
Cambrex announced today that it has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly's biotech collaborators.
December 5, 2024
by PR Newswire
Where Lies the Competitiveness of China's New Drugs for Central Nervous System?
The Global Challenges and Opportunities of the R&D of New Drugs for Central Nervous System
October 18, 2024
by Prof. Zhang
Sales volume of Dupixent reaching USD 5.35 billion in H1 of the year, setting off a R&D boom of IL-4R in China
Under the influence of Dupixent, there is a R&D boom of IL-4 targets in China.
August 28, 2023
by PharmaSources/Yefenghong
35 per 100 CNY Earned for Marketing, How Much is the Sales Expense Ratio of Chinese Pharmaceutical Companies?
High sales expenses not only increase the cost of medical treatment and medication, but also affect the healthy development of the domestic pharmaceutical industry. Therefore, anti-corruption is imperative and imminent.
August 17, 2023
by PharmaSources/Caicai
AI powers drug R&D OpenAI technology promises a new technological revolution
With the development of technology, AI technology has been widely used in several medical field scenarios.
April 27, 2023
by PharmaSources
Weekly Pharma News Review | PharmaSources.com (1114-1118)
The news review of this week is from November 14 to 18, covering a total of 23 pieces of information in 3 sections, i.e., drug review, R&D, and business.
November 21, 2022
by PharmaSources.com
Weekly Pharma News Review | PharmaSources.com (1107-1111)
The news review of this week is from November 7 to 11, covering a total of 26 pieces of information in 3 sections, i.e., drug review, R&D, and business.
November 14, 2022
by PharmaSources.com
Weekly Pharma News Review | PharmaSources.com (1031-1104)
The news review of this week is from October 31 to November 4, covering a total of 25 pieces of information in 3 sections, i.e., drug review, R&D, and business.
November 8, 2022
by PharmaSources.com
Weekly Pharma News Review | PharmaSources.com (1024-1028)
The news review of this week is from October 24 to 28, covering a total of 23 pieces of information in 4 sections, i.e., drug review, R&D, business and listing.
October 31, 2022
by PharmaSources.com
Weekly Pharma News Review | PharmaSources.com (1017-1021)
The news review of this week is from October 17 to 21, covering a total of 21 pieces of information in 3 sections, i.e., drug review, R&D, and listing.
October 24, 2022
by PharmaSources.com